Both　ursolic　acid　(UA)　and　sorafenib　(Sora)　have　been　generally　utilized　in　cancer　treatment,　and　the　combination　of　the　two　has　also　shown　a　good　anti-tumor　effect.　However,　single-agent　therapy　for　Hepatocellular　carcinoma　(HCC)　has　the　disadvantages　of　multi-drug　resistance,　poor　water　solubility　and　low　bioavailability,　and　the　application　of　traditional　nanocarrier　materials　is　limited　due　to　their　low　drug　loading　and　low　carrierrelated　toxicity.　Therefore,　we　prepared　US　NPs　with　different　proportions　of　UA　and　Sora　by　solvent　exchange　method　for　achieving　synergistic　HCC　therapy.　US　NPs　had　suitable　particle　size,　good　dispersibility　and　storage　stability,　which　synergistically　inhibited　the　proliferation　of　HepG2　cells,　SMMC7721　cells　and　H22　cells.　In　addition,　we　also　proved　that　US　NPs　were　able　to　suppress　the　migration　of　HepG2　cells　and　SMMC7721　cells　and　reduce　the　adhesion　ability　and　colony　formation　ability　of　these　cells.　According　to　the　results,　US　NPs　could　degrade　the　membrane　potential　of　mitochondrial,　participate　in　cell　apoptosis,　and　synergistically　induce　autophagy.　Collectively,　the　carrier-free　US　NPs　provide　new　strategies　for　HCC　treatment　and　new　ideas　for　the　development　of　novel　nano-drug　delivery　systems　containing　UA　and　Sora.